Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Equity Income (2021 - 2026)

Corvus Pharmaceuticals' Equity Income history spans 6 years, with the latest figure at -$599000.0 for Q1 2026.

  • Quarterly Equity Income fell 11.13% to -$599000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Mar 2026, up 49.19% year-over-year, with the annual reading at -$2.0 million for FY2025, 38.76% up from the prior year.
  • Equity Income came in at -$599000.0 for Q1 2026, up from -$707000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $236000.0 in Q1 2024 to a low of -$4.6 million in Q4 2022.
  • The 5-year median for Equity Income is -$865000.0 (2023), against an average of -$1.2 million.
  • Year-over-year, Equity Income crashed 941.0% in 2022 and then soared 113.63% in 2024.
  • Corvus Pharmaceuticals' Equity Income stood at -$4.6 million in 2022, then skyrocketed by 69.73% to -$1.4 million in 2023, then crashed by 54.84% to -$2.2 million in 2024, then surged by 67.48% to -$707000.0 in 2025, then grew by 15.28% to -$599000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Equity Income are -$599000.0 (Q1 2026), -$707000.0 (Q4 2025), and -$323000.0 (Q3 2025).